Analysts Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Price Target at $797.75

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been assigned an average recommendation of “Moderate Buy” from the twenty-six brokerages that are currently covering the firm, MarketBeat reports. Ten research analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $793.7391.

Several analysts have recently weighed in on REGN shares. Barclays reduced their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Finally, Morgan Stanley upped their price objective on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st.

Insider Activity

In related news, Director Huda Y. Zoghbi sold 800 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 31.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the transaction, the director owned 603 shares in the company, valued at $482,400. This represents a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,400 shares of company stock valued at $1,090,030. Insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Insigneo Advisory Services LLC boosted its stake in Regeneron Pharmaceuticals by 3.0% during the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 13 shares during the period. Arjuna Capital grew its position in Regeneron Pharmaceuticals by 3.2% during the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock worth $353,000 after purchasing an additional 14 shares during the last quarter. Guardian Wealth Advisors LLC NC increased its stake in Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 14 shares during the period. TD Private Client Wealth LLC increased its stake in Regeneron Pharmaceuticals by 9.7% in the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 15 shares during the period. Finally, MCF Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 15 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $805.97 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals has a fifty-two week low of $541.00 and a fifty-two week high of $821.11. The firm has a market capitalization of $82.98 billion, a PE ratio of 19.92, a price-to-earnings-growth ratio of 1.36 and a beta of 0.22. The stock’s 50-day simple moving average is $672.43 and its 200-day simple moving average is $713.71.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the company posted $12.81 earnings per share. As a group, equities research analysts forecast that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron agreed to collaborate with Parabilis Medicines on antibody-Helicon conjugates, providing Parabilis with $125 million in upfront consideration and an equity investment. Regeneron could also receive as much as $2.2 billion in milestone payments, plus tiered royalties, if the programs succeed. The deal expands Regeneron’s drug-development capabilities and adds potential long-term pipeline value. Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
• Positive Sentiment: Recent fundamentals remain supportive: Regeneron’s latest quarterly results exceeded analyst expectations, with earnings per share of $14.29 versus a $10.16 consensus and revenue of $4.29 billion versus estimates of $3.82 billion. Revenue increased 16.7% year over year, reinforcing investor confidence in the business and its ability to fund pipeline development.
• Neutral Sentiment: Directors Huda Y. Zoghbi and Kathryn Guarini sold $640,000 and $320,000 of stock, respectively, at approximately $800 per share. Both transactions were executed under pre-arranged Rule 10b5-1 plans, which reduces their usefulness as indicators of current management sentiment. Director Sale Filing
• Negative Sentiment: Multiple law firms publicized a securities class action tied to allegations that Regeneron misled investors about the prospects of its Phase 3 fianlimab-Libtayo trial for advanced melanoma. The trial’s failed primary endpoint reportedly erased about $11 billion in market value and may increase concerns about litigation expenses, disclosure practices and the oncology pipeline. Investors seeking lead-plaintiff status face a September 14, 2026 deadline. Regeneron Class Action Lawsuit Notice

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.